Abstract：Objective To explore the association between the lipid-regulating effect of Simvastatin with I405V and 1696G/A polymorphisms in cholesteryl ester transfer protein (CETP) gene. Methods Two hundred and thirty-three cases of patients with dyslipidemia treated in Affiliated Hospital of Guangdong Medical University from February 2008 to June 2010 were selected. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique was used to detect the genotype frequency distribution of I405V and 1696G/A polymorphisms, and the change of each blood-fat index among different genotypes was compared before and after Simvastatin treatment. Results The distribution of II, IV and VV genotype of I405V polymorphism were 63 cases, 101 cases and 69 cases respectively. The GG, GA and AA genotype distribution of 1696G/A polymorphism were 167 cases, 45 cases and 21 cases respectively. After Simvastatin treatment, the decline of triacylglycerol (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and very low density lipoprotein cholesterol (VLDL-C) in II genotype patients was the most obvious (P ＜ 0.05 or P ＜ 0.01). There was no statistically significant difference in the change of blood lipid levels among all kinds of 1696G/A genotype patients (P ＞ 0.05). Conclusion The effect of Simvastatin on blood lipid is related to the I405V polymorphism of CETP gene.
[1] Kakara M，Nomura H，Fukae M，et al. Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records [J]. Br J Clin Pharmacol，2014，78（4）：824-835.
[2] Pajohanfar NS，Mohebbi E，Hosseini-Bandegharaei A，et al. Simvastatin prevents morphine-induced tolerance and dependence in mice [J]. Biomed Pharmacother，2017，93：406-411.
[3] Gelissen IC，Mclachlan AJ. The pharmacogenomics of statins [J]. Pharmacol Res，2014，88（9）：99-106.
[4] Teramoto T，Daida H，Ikewaki K，et al. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia [J]. Atherosclerosis，2017，261：69-77.
[5] Orsoni A，Thérond P，Tan R，et al. Statin action preferentially enriches HDL3 in polyunsaturated phospholipids and plasmalogens in atherogenic mixed dyslipidemia：relevance to enhanced reduction of LDL-derived phospholipid hydroperoxides to inactive hydroxides [J]. J Lipid Res，2016， 57（11）：2073-2087.
[6] Luzum JA，Theusch E，Taylor KD，et al. Individual and Combined Associations of Genetic Variants in CYP3A4，CYP3A5，and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations [J]. J Cardiovasc Pharmacol，2015，66（1）：80-85.
[7] Lauer ME，Graff-Meyer A，Rufer AC，et al. Cholesteryl ester transfer between lipoproteins does not require a ternary tunnel complex with CETP [J]. J Struct Biol，2016，194（2）：191-198.
[8] Blauw LL，de Mutsert R，Lamb HJ，et al. Serum CETP concentration is not associated with measures of body fat：The NEO study [J]. Atherosclerosis，2016，246：267-273.
[9] Bustami J，Sukiasyan A，Kupcinskas J，et al. Cholesteryl ester transfer protein（CETP）I405V polymorphism and cardiovascular disease in eastern European Caucasians-a cross-sectional study [J]. BMC Geriatrics，2016，16：144.
[10] Karimpour F，Mohammadzadeh G，Kheirollah A，et al. Association of I405V polymorphism of colesteryl ester transfer protein gene with coronary artery disease in men with type 2 diabetes [J]. ARYA Atheroscler，2016，12（2）：68-75.
[11] Tamminen M，Kakko S，Kes?覿niemi YA，et al. A polymorphic site in the 3′ untranslated region of the cholesteryl ester transfer protein（CETP）gene is associated with low CETP activity [J]. Atherosclerosis，1996，124（2）：237-247.
[12] 寿峰勤，金轶，杨小英.胆固醇酯转运蛋白I405V多态位点与辛伐他汀对血脂异常患者调脂疗效的关联性[J].中国生化药物杂志，2014，34（3）：48-51.
[13] Vargasalarcon G，Perezmendez O，Herreramaya G，et al. CETP and LCAT Gene Polymorphisms Are Associated with High-Density Lipoprotein Subclasses and Acute Coronary Syndrome [J]. Lipids，2018，53（2）：157-166.
[14] Lin S，Dai R，Lin R. A meta-analytic evaluation of cholesteryl ester transfer protein（CETP）C-629A polymorphism in association with coronary heart disease risk and lipid changes [J]. Oncotarget，2016，8（2）：2153-2163.
[15] Rashid S，Sniderman A，Melone M，et al. Elevated cholesteryl ester transfer protein（CETP）activity，a major determinant of the atherogenic dyslipidemia，and atherosclerotic cardiovascular disease in South Asians [J]. Eur J Prev Cardiol，2015，22（4）：468-477.
[16] Kolovou G，Kolovou V，Mihas C，et al. Cholesteryl ester transfer protein and ATP-binding cassette transporter A1 genotype alter the atorvastatin and simvastatin efficacy： time for genotype-guided therapy?[J]. Angiology，2013， 64（4）：266-272.
[17] Li Q，Huang P，He QC，et al. Association between the CETP polymorphisms and the risk of Alzheimer′s disease，carotid atherosclerosis，longevity，and the efficacy of statin therapy [J]. Neurobiol Aging，2014，35（6）：13-23.
[18] Ference BA，Kastelein JJP，Ginsberg HN，et al. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk [J]. Jama，2017，318（10）：947-956.
[19] Shimada A，Kimura H，Oida K，et al. Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association [J]. Lipids Health Dis，2016，15：57.
[20] Sundermann EE，Wang C，Katz M，et al. Cholesteryl ester transfer protein genotype modifies the effect of apolipoprotein ε4 on memory decline in older adults [J]. Neurobiol Aging，2016，41：200.e7-200.e12.
2019, Vol. 16 
京公网安备 11010502046598号